Int. J. Mol. Sci. 2013, 14(9), 19257-19275; doi:10.3390/ijms140919257
Review

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer

1,2email, 2email and 2,3,* email
Received: 18 July 2013; in revised form: 13 August 2013 / Accepted: 15 August 2013 / Published: 23 September 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to chemotherapy but eventually relapse due to the development of drug resistance. Currently, there are no biological markers that can be used to predict patient response to chemotherapy. However, it is clear that mutations in the tumor suppressor gene TP53, which occur in 96% of serous ovarian tumors, alter the core molecular pathways involved in drug response. One subtype of TP53 mutations, widely termed gain-of-function (GOF) mutations, surprisingly converts this protein from a tumor suppressor to an oncogene. We term the resulting change an oncomorphism. In this review, we discuss particular TP53 mutations, including known oncomorphic properties of the resulting mutant p53 proteins. For example, several different oncomorphic mutations have been reported, but each mutation acts in a distinct manner and has a different effect on tumor progression and chemoresistance. An understanding of the pathological pathways altered by each mutation is necessary in order to design appropriate drug interventions for patients suffering from this deadly disease.
Keywords: TP53; oncomorphic mutation; ovarian cancer; mutant p53; chemoresistance
PDF Full-text Download PDF Full-Text [1147 KB, uploaded 19 June 2014 05:09 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Brachova, P.; Thiel, K.W.; Leslie, K.K. The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 19257-19275.

AMA Style

Brachova P, Thiel KW, Leslie KK. The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(9):19257-19275.

Chicago/Turabian Style

Brachova, Pavla; Thiel, Kristina W.; Leslie, Kimberly K. 2013. "The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer." Int. J. Mol. Sci. 14, no. 9: 19257-19275.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert